New York, November 16
Moderna Inc said on Monday its experimental vaccine was 94.5 percent effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second US company in a week to report results that far exceed expectations.
Together with Pfizer Inc's vaccine, also shown to be more than 90 percent effective, and pending more safety data and regulatory review, the United States could have two vaccines authorised for emergency use in December with as many as 60 million doses of vaccine available by the year's end.
Source